TAMOXIFEN OR CYPROTERONE-ACETATE IN COMBINATION WITH BUSERELIN ARE INEFFECTIVE IN PATIENTS WITH PANCREATIC ADENOCARCINOMA

Experimental evidence and preliminary clinical data suggest a responsi veness of pancreatic adenocarcinoma to sex hormones and LH-RH agonists . In this study, we investigated the effect of the antiestrogen tamoxi fen and the antiandrogen cyproterone acetate in combination with the L H-RH agonist buserelin in 9 patients with unresectable pancreatic aden ocarcinoma. In all patients the disease was progressive under this the rapeutic regimen. In conclusion, complete androgen blockade and anties trogens in combination with LH-RH agonist cannot be recommended in pat ients with widespread pancreatic adenocarcinoma.